Research Articles

Stem cell-based approaches can induce poststroke recovery via mechanisms, such as neuronal replacement, promotion of angiogenesis, induction of brain plasticity, reduction of cell death, or immunomodulation.

This study provides strong evidence that autologous hematopoietic stem cell transplantation offers superior long-term clinical outcomes compared to two of the most effective current disease-modifying therapies for relapsing multiple sclerosis, particularly in terms of preventing relapses and maintaining sustained clinical benefit over a 5-year follow-up period.

Changes in neurological deficits and improvements in function were compared between two groups for 1 year after symptom onset. Patients treated with autologous MSCs showed significant improvement in both cognition and mobility.

MSC therapy is safe and effective in treating IS by improving the neurological deficits, motor function and daily life quality of patients.

This study shows the key positive finding that this treatment approach demonstrated both safety and clinical benefit in patients with chronic discogenic low back pain, with no adverse events reported during the 1-year follow-up period.

Numerous studies reported better results when the mesenchymal stem cells were used in co-culture with other cells or used in scaffolds. Mesenchymal stem cells were also found to have an immune-modulatory role, which can improve surgical outcome.

All of the children demonstrated neurological improvement, with significant reductions in the number of both epileptic seizures and SE episodes, with an improved quality of life.

This study supports the benefit of intrathecal administration of autologous MSCs for the treatment of neuropathic pain in patients with spinal cord injuries.

Patients receiving MSCs saw significant improvement in standing and walking time, with reduced need for medication.

Injection of imesenchymal stem cells directly into damaged spinal discs reduce back pain and help heal the disc tissue, potentially avoiding the need for surgery. This treatment works best when used early in disc problems and could help keep the spine working normally, preventing further damage and the need for more invasive procedures later.

In certain autoimmune diseases AHSCT can be good choice when conventional therapy failed.

Hematopoietic stem cell transplantation (HSCT) has been proposed as a therapeutic option for patients with Systemic Lupus Erythematosus (SLE) refractory to standard therapy. This therapeutic approach has been applied to other severe autoimmune diseases refractory to standard therapy with promising results.